Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) CFO Sells 2,899 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) CFO Jason Alger sold 2,899 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $7.39, for a total transaction of $21,423.61. Following the completion of the sale, the chief financial officer now owns 114,106 shares in the company, valued at approximately $843,243.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Health Catalyst Stock Up 4.9 %

Shares of Health Catalyst stock traded up $0.37 on Tuesday, reaching $7.85. The company’s stock had a trading volume of 534,986 shares, compared to its average volume of 582,994. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.70. The company has a market capitalization of $463.42 million, a price-to-earnings ratio of -4.24 and a beta of 1.31. The firm’s fifty day simple moving average is $6.89 and its two-hundred day simple moving average is $6.88.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. The firm’s revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.21) EPS. As a group, research analysts predict that Health Catalyst, Inc. will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors have recently bought and sold shares of the business. Primecap Management Co. CA raised its holdings in shares of Health Catalyst by 26.7% in the 4th quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company’s stock valued at $13,145,000 after purchasing an additional 299,139 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in shares of Health Catalyst in the first quarter worth about $8,780,000. ClariVest Asset Management LLC grew its stake in Health Catalyst by 303.9% in the 1st quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company’s stock valued at $2,126,000 after acquiring an additional 212,425 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Health Catalyst by 38.3% during the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after acquiring an additional 200,494 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its position in shares of Health Catalyst by 386.6% in the first quarter. Los Angeles Capital Management LLC now owns 56,785 shares of the company’s stock valued at $428,000 after buying an additional 45,115 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Piper Sandler lowered their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Evercore ISI decreased their target price on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Tuesday, July 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Tuesday, August 20th. Stephens reduced their target price on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price target on shares of Health Catalyst in a report on Tuesday, May 21st. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Health Catalyst currently has a consensus rating of “Moderate Buy” and an average target price of $11.42.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.